Benefits Of Avandia, Actos Outweigh Risks – EMEA
This article was originally published in The Pink Sheet Daily
Executive Summary
EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.
You may also be interested in...
Avandia Monotherapy Use Curtailed in Canada
Cardiac safety concerns fuel Health Canada to recommend rosiglitazone as second-line treatment for diabetes.
Avandia Monotherapy Use Curtailed in Canada
Cardiac safety concerns fuel Health Canada to recommend rosiglitazone as second-line treatment for diabetes.
BART Sends Bayer’s Trasylol Off The Market
Bayer “temporarily” phases out proteinase inhibitor after top-line data show 50% higher death rate for Trasylol versus comparators.